Chronic Active Arthritis Driven by Macrophages Without Involvement of T Cells: A Novel Experimental Model of Rheumatoid ArthritisShow others and affiliations
2018 (English)In: Arthritis & Rheumatology, ISSN 2326-5191, E-ISSN 2326-5205, Vol. 70, no 8, p. 1343-1353Article in journal (Refereed) Published
Abstract [en]
OBJECTIVE: To develop a new chronic rheumatoid arthritis model that is driven by the innate immune system.
METHODS: Injection of a cocktail of 4 monoclonal antibodies against type II collagen, followed on days 5 and 60 by intraperitoneal injections of mannan (from Saccharomyces cerevisiae), was used to induce development of chronic arthritis in B10.Q mice. The role of the innate immune system as compared to the adaptive immune system in this arthritis model was investigated using genetically modified mouse strains.
RESULTS: A new model of chronic relapsing arthritis was characterized in B10.Q mice, in which a persistently active, chronic disease was found. This relapsing disease was driven by macrophages lacking the ability to mount a reactive oxygen species response against pathogens, and was associated with the classical/alternative pathway, but not the lectin pathway, of complement activation. The disease was independent of Fcγ receptor type III, and also independent of the activity of adaptive immune cells (B and T cells), indicating that the innate immune system, involving complement activation, could be the sole driver of chronicity.
CONCLUSION: Chronic active arthritis can be driven innately by macrophages without the involvement of T and B cells in the adaptive immune system. © 2018, American College of Rheumatology.
Place, publisher, year, edition, pages
Hoboken: John Wiley & Sons, 2018. Vol. 70, no 8, p. 1343-1353
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:hh:diva-48396DOI: 10.1002/art.40482ISI: 000439922300022PubMedID: 29513929Scopus ID: 2-s2.0-85050645467OAI: oai:DiVA.org:hh-48396DiVA, id: diva2:1703123
Funder
Knut and Alice Wallenberg Foundation
Note
Supported by the Academy of Finland, the Sigrid Jusélius Foundation, the National Doctoral Programme in Informational and Structural Biology, the Turku University Foundation, the King Gustaf V's 80-Year Foundation, the Finnish Cultural Foundation, the Varsinais-Suomi Regional Fund, the Swedish Foundation for Strategic Research, the KA Wallenberg Foundation, the Swedish Research Council, and the Guangdong Province (team grant 201001Y04675344).
Dr. Collin has received consulting fees from Hansa Medical AB (less than $10,000) and is listed as inventor on patents held by Hansa Medical AB for using EndoS as a treatment for antibody-mediated diseases, for which he receives royalties, and on patents held by Genovis AB for the biotechnological use of EndoS.
2022-10-122022-10-122022-10-18Bibliographically approved